The very medicines that save lives can trigger bleeding inside the skull
Each year, nearly 800,000 Americans suffer a stroke, and the medicines that save their lives carry a cruel irony: they can cause the very brain bleeding they race to prevent. At the University of Southern California's Keck School of Medicine, researchers have spent years refining a compound that may finally resolve this paradox — a modified human protein that shields the brain while standard treatments do their work. The National Institutes of Health, persuaded by promising early results, has committed up to $30 million to find out whether that promise holds at scale.
- Current stroke treatments restore blood flow but trigger brain hemorrhage in up to 80% of patients — a trade-off that has shadowed the field for decades.
- An experimental drug, 3K3A-APC, cut hemorrhage rates by nearly 20 percentage points in Phase 2 trials, a result striking enough to draw $30 million in federal attention.
- The NIH's first $4 million installment launches RHAPSODY-2, a large Phase 3 trial designed to test whether the drug's protective effects translate into real reductions in death and disability.
- The USC team behind the trial includes the neurologist who helped develop tPA itself, lending the effort both deep credibility and a clear-eyed understanding of what is still unproven.
- The drug must now clear the highest bar in medicine — not just fewer bleeds on a chart, but measurably better lives for the 795,000 Americans struck each year.
Stroke moves fast, and so must its treatments — but the clot-busting drugs and mechanical interventions that save lives carry a punishing side effect: brain hemorrhage, which haunts roughly four in five patients who receive them. A research team at USC's Keck School of Medicine has spent years working on a compound they believe can change that equation.
The National Institute of Neurological Disorders and Stroke has awarded USC $4 million as the opening installment of a potential $30 million, six-year grant to test 3K3A-APC, a modified version of a protein the human body produces naturally. The drug is designed not to replace existing stroke treatments, but to work alongside them — stabilizing the blood-brain barrier while tPA or mechanical clot removal does its job.
The case for a larger trial rests on the earlier RHAPSODY study, in which hemorrhage rates among treated stroke patients fell from 86.5 percent to 67.4 percent. Published in the Annals of Neurology in 2019, those results were concrete enough to convince federal reviewers. Leading the effort is neurologist Patrick Lyden, who was part of the team that first proved tPA could reverse stroke — and who understands better than most what the drug's risks have cost patients over the years.
The new Phase 3 trial, RHAPSODY-2, will need to demonstrate more than reduced bleeding. It must show that patients actually recover better — fewer deaths, less lasting disability. That evidence will take years to accumulate. For now, the federal investment represents a considered wager that a naturally occurring human protein, carefully engineered, might finally let doctors treat stroke as aggressively as the disease demands.
Stroke kills fast. The approved treatments that save lives—clot-busting drugs and mechanical interventions—work best when given within hours of the attack. But they carry a brutal trade-off: the very medicines that restore blood flow to the brain can trigger bleeding inside the skull, a complication that haunts roughly four out of five patients who receive them, whether they know it or not.
Now a research team at USC's Keck School of Medicine has moved closer to changing that calculus. The National Institute of Neurological Disorders and Stroke has awarded $4 million as the first installment of what could grow to $30 million over six years to test an experimental drug called 3K3A-APC in a large-scale clinical trial. The money funds what researchers call a cerebroprotectant—a compound designed to work alongside existing stroke treatments, shoring up the brain's defenses while those treatments do their job.
The drug is a modified version of a protein the body makes naturally. In earlier human testing, led by neurologist Patrick Lyden at USC, it reduced the rate of treatment-related brain hemorrhage by nearly 20 percentage points. That finding was striking enough to convince federal reviewers that a bigger trial was worth funding. Lyden, who helped develop tPA—the first drug ever proven to reverse stroke—knows the stakes intimately. When tPA works, it works spectacularly: eight out of eighteen patients who receive it recover substantially within three months. But the enzyme it unleashes to dissolve clots can also rupture blood vessels in the brain. Mechanical interventions that thread catheters through vessels to pull out clots carry similar risks, damaging the delicate barrier that protects brain tissue from bleeding.
The earlier Phase 2 trial, called RHAPSODY, tested whether 3K3A-APC could stabilize that barrier. Researchers gave the drug to stroke patients receiving either tPA or mechanical intervention, then measured how many developed intracranial bleeding. The results were concrete: hemorrhage rates fell from 86.5 percent to 67.4 percent. Published in the Annals of Neurology in 2019, the findings suggested the drug's protective properties could translate to real patients in real time.
Berislav Zlokovic, director of the Zilkha Neurogenetic Institute at USC and a co-discoverer of the drug's neuroprotective properties, frames the stakes plainly. Stroke affects 795,000 Americans each year and remains a leading cause of death. The new trial, called RHAPSODY-2, will test whether 3K3A-APC can become a standard part of stroke care—given routinely alongside existing treatments to reduce the bleeding that currently limits how aggressively doctors can intervene.
The drug is being developed by ZZ Biotech, a private company collaborating with the USC team. The company's chief executive called the federal funding a validation of the Phase 2 results and expressed confidence in the larger trial ahead. But validation is not the same as proof. The Phase 3 trial will need to show not just that the drug reduces bleeding, but that patients actually recover better—that the protection translates to fewer deaths, less disability, better lives. That evidence will take time to gather. For now, the $4 million represents a bet that a naturally occurring human protein, engineered and refined, might finally close the gap between what stroke treatments can do and what they cost.
Notable Quotes
Perhaps as many as 80% of patients have brain bleeding after stroke without even knowing it. This could make a game-changing difference in stroke patient recovery.— Dr. Patrick Lyden, study principal investigator
The NINDS decision to provide grant funding further validates our RHAPSODY Phase 2 results, which established a strong link between treatment with our novel drug and reduced bleeding.— Kent Pryor, CEO of ZZ Biotech
The Hearth Conversation Another angle on the story
Why does a drug that already reduced bleeding by 20 percent need such a large Phase 3 trial? Isn't that already proof?
Phase 2 shows promise, but it's usually smaller and less rigorous. You need Phase 3 to confirm the effect holds up in a bigger, more diverse population, and more importantly, to show that reducing bleeding actually translates to better patient outcomes—fewer deaths, less disability. That's the real question.
So the drug doesn't cure stroke. It just makes the existing treatments safer?
Exactly. It's a companion drug. The clot-busters and mechanical interventions do the heavy lifting—they restore blood flow. This drug is meant to protect the brain while that's happening, reducing the collateral damage. It's a damage-control strategy.
You mentioned 80 percent of stroke patients have brain bleeding. That seems impossibly high.
It is striking. But much of it is microscopic—patients don't feel it, don't show obvious symptoms. The danger is that some of it progresses to larger, symptomatic bleeds that disable or kill. The drug aims to prevent that progression.
Dr. Lyden helped invent tPA, the first stroke drug. Does that make him biased toward this new drug?
It's fair to ask. But his track record suggests he's rigorous. He's been studying stroke treatment for decades. And the Phase 2 results were published in a peer-reviewed journal, not just announced. The NIH reviewers would have scrutinized the data carefully before committing $30 million.
What happens if RHAPSODY-2 fails?
Then the drug doesn't become standard care, and researchers go back to the drawing board. But the Phase 2 data was solid enough that the NIH thought it worth testing at scale. That's not a guarantee of success, but it's a reasoned bet.